Suppr超能文献

精氨酸加压素通过V1受体增加麻醉大鼠的肾钠排泄。

Arginine vasopressin increases renal sodium excretion in the anesthetized rat through V1 receptors.

作者信息

Musabayane C T, Forsling M L, Balment R J

机构信息

Department of Physiology, University of Zimbabwe, Harare, Zimbabwe.

出版信息

Ren Fail. 1997 Jan;19(1):23-32. doi: 10.3109/08860229709026257.

Abstract

We have previously suggested that the increase in renal Na+ excretion in response to physiological doses of arginine vasopressin (AVP) is not directly linked to the V2-mediated antidiuretic effect. In the present study we investigated the possible involvement of AVP V1 receptors in this natriuresis using a specific AVP V1 antagonist [1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid), 2-O-methyltyrosine arginine vasopressin, d(CH2)5[Tyr(Me)2]AVP, infused at a rate of 15 ng.min-1. Male anesthetized Sprague-Dawley rats were placed on a continuous jugular infusion of 0.077 M NaCl at 150 microL.min-1. After a 3-h equilibration period, samples were collected at 20-min intervals for 4 h for the determination of urine flow, and Na+ and K+ excretion rates. In those animals in which the effects of AVP were studied, a 1-h control period was allowed following which AVP was infused at 0.02-0.08 pmol.min-1 for 1 h 20 min in separate groups of animals and then returned to the infusate alone for the last part of the experiment. In other groups the AVP V1 antagonist d(CH2)5[Tyr(Me)2]AVP (15 ng.min-1) alone or in combination with AVP (at various dose rates) was also administered for 1 h 20 min. All dose rates of AVP produced an antidiuresis which was associated significantly to increased Na+ excretion rate. However, AVP administration at the median dose rate (0.04 pmol.min-1) significantly (p < 0.01) decreased the amount of urine voided by comparison with control animals (6.34 +/- 1.05 ml vs. 11.892 +/- 0.03 mL, n = 7) although the urinary Na+ was elevated (967 +/- 18 mumol, vs. 742 +/- 81 mumol, n = 7). This AVP-induced increase in urinary Na+ loss was abolished in animals receiving combined AVP (0.04 pmol.min-1) and AVP V1 antagonist (674 +/- 47 mumol, n = 7) although the antidiuretic effect persisted. Urine flow and Na+ excretion rates remained unchanged in groups of animals administered AVP V1 antagonist alone. In all groups, the K+ excretion rates did not significantly differ. It is concluded that the V1 receptor mediates the natriuretic effect of AVP.

摘要

我们之前曾提出,生理剂量的精氨酸加压素(AVP)引起的肾钠排泄增加与V2介导的抗利尿作用并无直接关联。在本研究中,我们使用一种特异性AVP V1拮抗剂[1-(β-巯基-β,β-环戊亚甲基丙酸),2-O-甲基酪氨酸精氨酸加压素,d(CH2)5[Tyr(Me)2]AVP,以15 ng·min-1的速率输注]来研究AVP V1受体在这种利钠作用中可能的参与情况。将雄性麻醉的Sprague-Dawley大鼠通过颈静脉以150 μL·min-1的速率持续输注0.077 M NaCl。经过3小时的平衡期后,每隔20分钟采集样本,持续4小时,以测定尿流量以及钠和钾的排泄率。在研究AVP作用的那些动物中,先有1小时的对照期,之后在不同组的动物中以0.02 - 0.08 pmol·min-1的速率输注AVP 1小时20分钟,然后在实验的最后阶段仅恢复输注液。在其他组中,单独或与AVP(以不同剂量率)联合给予AVP V1拮抗剂d(CH2)5[Tyr(Me)2]AVP(15 ng·min-1),持续1小时20分钟。所有剂量率的AVP均产生抗利尿作用,且与钠排泄率增加显著相关。然而,以中位剂量率(0.04 pmol·min-1)给予AVP时,与对照动物相比,排尿量显著(p < 0.01)减少(6.34 ± 1.05 ml对11.892 ± 0.03 mL,n = 7),尽管尿钠升高(967 ± 18 μmol对742 ± 81 μmol,n = 7)。在接受联合AVP(0.04 pmol·min-1)和AVP V1拮抗剂的动物中,这种AVP诱导的尿钠丢失增加被消除(674 ± 47 μmol,n = 7),尽管抗利尿作用持续存在。单独给予AVP V1拮抗剂的动物组中尿流量和钠排泄率保持不变。在所有组中,钾排泄率没有显著差异。结论是V1受体介导了AVP的利钠作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验